A live attenuated vaccine against herpes zoster (Zostavax) was licensed in Australia in 2006. The vaccine contains approximately 14 times more attenuated varicella zoster virus (Oka strain) than the licensed chickenpox vaccines – this higher concentration is needed to produce a T-cell boosting response.
Since November 2016 the live vaccine has been offered through the National Immunisation Program to adults aged 70 years, and to those aged 71–79 years in a five-year catch-up program. It is contraindicated in individuals with significant immunosuppression due to disease or therapy.
Zoster vaccine is funded for people aged 70–79 years because they are expected to benefit the most. People in this age group have a higher risk of herpes zoster and postherpetic neuralgia compared to those aged 50–69 years.
Zostavax is registered for use from 50 years of age and is recommended in the Australian Immunisation Handbook for all immunocompetent adults aged 60 years and older.17 Routine administration from 50–59 years is not recommended because of the relatively low disease incidence and because waning vaccine immunity in the 5–10 years after vaccination would result in insufficient protection when reaching an older age.
Age 70–79 years is considered the best time to target the one-dose vaccine so protection lasts until people reach their 80s, when disease risk is highest. The efficacy of the vaccine is low after 80 years of age, but individual benefit is still likely.
People aged 50–69 years and over 80 years who wish to receive the vaccine have to obtain a prescription and pay for it. Zoster vaccination is recommended for household contacts (aged ≥50 years) of anyone who is immunocompromised (currently or expected to be). This reduces the likelihood of exposure to shedding virus for the immunocompromised person.17
The vaccine can be given at the same visit as other inactivated or live vaccines, including pneumococcal vaccine.17 It is also safe to give to someone who has had a previous episode of herpes zoster, to prevent recurrence. However, because herpes zoster itself provides an immune boost, vaccination is not recommended until at least 1–3 years after the initial herpes zoster episode.17
The lifetime risk of recurrent herpes zoster is 1–5%.18,19 Repeat (booster) doses of Zostavax are not currently recommended or funded but a subsequent dose 10 years after a first dose is safe and results in an immune boost.20 Checking for evidence of past chickenpox by serology is not required before vaccination, except in special circumstances such as HIV infection or before transplant.